Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)

Numerous placebo-controlled studies have demonstrated the ability of ketamine, an NMDA receptor antagonist, to induce rapid (within hours), transient antidepressant effects when administered intravenously (IV) at subanesthetic doses (0.5 mg/kg over 40 min). However, the optimal antidepressant dose r...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Molecular psychiatry Ročník 25; číslo 7; s. 1592 - 1603
Hlavní autori:	Fava, Maurizio, Freeman, Marlene P, Flynn, Martina, Judge, Heidi, Hoeppner, Bettina B, Cusin, Cristina, Ionescu, Dawn F, Mathew, Sanjay J, Chang, Lee C, Iosifescu, Dan V, Murrough, James, Debattista, Charles, Schatzberg, Alan F, Trivedi, Madhukar H, Jha, Manish K, Sanacora, Gerard, Wilkinson, Samuel T, Papakostas, George I
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Nature Publishing Group 01.07.2020
Predmet:	Adult Antidepressants Antidepressive Agents - therapeutic use Blood pressure Depression - drug therapy Depressive Disorder, Treatment-Resistant - drug therapy Double-Blind Method Double-blind studies Female Glutamic acid receptors (ionotropic) Humans Infusions, Intravenous Intravenous administration Ketamine Ketamine - administration & dosage Ketamine - therapeutic use Male Mental depression Midazolam Middle Aged N-Methyl-D-aspartic acid receptors Placebos Treatment Outcome Treatment resistance
ISSN:	1359-4184, 1476-5578, 1476-5578
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!